MC2-01 + irradiation

MC2-01 is a topical fixed-dose combination cream containing calcipotriene (0.005%) and betamethasone dipropionate (0.064%), developed using Polyaphron Dispersion (PAD) Technology to improve stability, cosmetic acceptability, and patient compliance for the treatment of mild-to-moderate plaque psoriasis. The formulation is designed to be non-greasy, quickly absorbed, and moisturizing. The mechanism of action combines the effects of a vitamin D analog (calcipotriene), which modulates keratinocyte proliferation and differentiation via the vitamin D receptor, with a potent corticosteroid (betamethasone dipropionate), which exerts anti-inflammatory effects through glucocorticoid receptor agonism[1][2][3][6]. \nThe phrase "+ irradiation" refers to clinical studies assessing photoallergic potential by applying the cream followed by controlled skin irradiation; it does not indicate that "irradiation" is an active drug component or ingredient[1]. \nMC2 Therapeutics developed this product as an improved alternative to existing calcipotriene/betamethasone formulations for psoriasis.

Brand names

MC2-01 PAD CreamMC-2-01 PAD CreamMC 2-01 PAD Cream

Other names

calcipotriene and betamethasone dipropionate PAD creamCAL/BDP PAD creamMC2-01 CreamMC-2-01 CreamMC 2-01 Cream